| Name | Title | Contact Details |
|---|
CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Our technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Our miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients. Due to their small size, durability, and lack of wires and batteries, our sensors are designed to be permanently implanted into the cardiovascular system. Using radiofrequency, or RF, energy, our sensors transmit real-time data to an external electronics module, which then communicates this information to the patient’s physician.
Second Sight is a Sylmar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CCG MetaMedia is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Oerth Bio™, we are on a mission to change perceptions of agricultural chemistry We are leading a new and transformative approach to crop protection, crop health and healthy food by leveraging our proprietary PROTAC® protein degraders, or proteolysis-targeting chimeras. PROTAC protein degraders work by harnessing the plant`s own natural protein disposal system to degrade and remove unwanted proteins. We are an early-stage agriculture biotechnology company located in the heart of downtown Durham, North Carolina.
Ophelia is a digital provider of medication-assisted treatment (MAT) for opioid use disorder (OUD), committed to making evidence-based treatment universally accessible. Its mission is to remove barriers for the 80% of Americans with OUD who are unable to access care and the 50,000+ MAT-licensed clinicians who are unable to treat patients due to a lack of infrastructure, training, and support. At its core is the Ophelia Care Model, a team-based clinical model and software platform developed by leading experts in addiction medicine and psychiatry. Ophelia is licensed to provide care in 36 states and contracted with Medicaid, Medicare, and Commercial insurers covering 85 million American lives.